Drug intelligence / Profile preview

CD19-directed CAR-T (IL-18 expressing)

Development stage: Preclinical
Lead developer: University of Pennsylvania
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD19-directed CAR-T (IL-18 expressing) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by The Second Xiangya Hospital of Central South University. This cell-based biologic consists of patient-derived T cells genetically modified to express a CAR specific for the CD19 antigen, a marker prevalent on B-cell malignancies. Additionally, the cells are engineered to co-express interleukin-18 (IL-18), a pro-inflammatory cytokine designed to augment the anti-tumor immune response, improve the expansion and persistence of the CAR-T cells, and modulate the tumor microenvironment. The therapy is currently being evaluated in early-phase clinical trials for various B-cell malignancies and other cancers.

Other names: CD19-directed CAR-T + IL-18 expressingCART-IL18CART-IL-18CART-IL 18

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CD19-directed CAR-T (IL-18 expressing).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-directed CAR-T (IL-18 expressing).

Explore the full profile